672 related articles for article (PubMed ID: 31402908)
1. Tuning the Tumor Myeloid Microenvironment to Fight Cancer.
Jahchan NS; Mujal AM; Pollack JL; Binnewies M; Sriram V; Reyno L; Krummel MF
Front Immunol; 2019; 10():1611. PubMed ID: 31402908
[TBL] [Abstract][Full Text] [Related]
2. Allies or Enemies-The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment.
Haas L; Obenauf AC
Front Immunol; 2019; 10():2746. PubMed ID: 31849950
[TBL] [Abstract][Full Text] [Related]
3. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
Front Immunol; 2018; 9():1288. PubMed ID: 29915603
[TBL] [Abstract][Full Text] [Related]
4. Myeloid cell heterogeneity in cancer: not a single cell alike.
Kiss M; Van Gassen S; Movahedi K; Saeys Y; Laoui D
Cell Immunol; 2018 Aug; 330():188-201. PubMed ID: 29482836
[TBL] [Abstract][Full Text] [Related]
5. Interactions among myeloid regulatory cells in cancer.
Umansky V; Adema GJ; Baran J; Brandau S; Van Ginderachter JA; Hu X; Jablonska J; Mojsilovic S; Papadaki HA; Pico de Coaña Y; Santegoets KCM; Santibanez JF; Serre K; Si Y; Sieminska I; Velegraki M; Fridlender ZG
Cancer Immunol Immunother; 2019 Apr; 68(4):645-660. PubMed ID: 30003321
[TBL] [Abstract][Full Text] [Related]
6. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
Front Immunol; 2018; 9():2250. PubMed ID: 30349530
[TBL] [Abstract][Full Text] [Related]
7. Context Drives Diversification of Monocytes and Neutrophils in Orchestrating the Tumor Microenvironment.
Jeong J; Suh Y; Jung K
Front Immunol; 2019; 10():1817. PubMed ID: 31474975
[TBL] [Abstract][Full Text] [Related]
8. Tracking Monocytes and Macrophages in Tumors With Live Imaging.
Laviron M; Combadière C; Boissonnas A
Front Immunol; 2019; 10():1201. PubMed ID: 31214174
[TBL] [Abstract][Full Text] [Related]
9. Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation.
Amodio G; Cichy J; Conde P; Matteoli G; Moreau A; Ochando J; Oral BH; Pekarova M; Ryan EJ; Roth J; Sohrabi Y; Cuturi MC; Gregori S
Cancer Immunol Immunother; 2019 Apr; 68(4):661-672. PubMed ID: 30357490
[TBL] [Abstract][Full Text] [Related]
10. Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression.
Awad RM; De Vlaeminck Y; Maebe J; Goyvaerts C; Breckpot K
Front Immunol; 2018; 9():1977. PubMed ID: 30233579
[TBL] [Abstract][Full Text] [Related]
11. Myeloid Cells as Targets for Therapy in Solid Tumors.
Cotechini T; Medler TR; Coussens LM
Cancer J; 2015; 21(4):343-50. PubMed ID: 26222088
[TBL] [Abstract][Full Text] [Related]
12. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.
Ostrand-Rosenberg S; Sinha P; Beury DW; Clements VK
Semin Cancer Biol; 2012 Aug; 22(4):275-81. PubMed ID: 22313874
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive Immature Myeloid Cell Generation Is Controlled by Glutamine Metabolism in Human Cancer.
Wu WC; Sun HW; Chen J; OuYang HY; Yu XJ; Chen HT; Shuang ZY; Shi M; Wang Z; Zheng L
Cancer Immunol Res; 2019 Oct; 7(10):1605-1618. PubMed ID: 31387898
[TBL] [Abstract][Full Text] [Related]
14. Targeting myeloid cells in the tumor sustaining microenvironment.
Schupp J; Krebs FK; Zimmer N; Trzeciak E; Schuppan D; Tuettenberg A
Cell Immunol; 2019 Sep; 343():103713. PubMed ID: 29129292
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression.
Devalaraja S; To TKJ; Folkert IW; Natesan R; Alam MZ; Li M; Tada Y; Budagyan K; Dang MT; Zhai L; Lobel GP; Ciotti GE; Eisinger-Mathason TSK; Asangani IA; Weber K; Simon MC; Haldar M
Cell; 2020 Mar; 180(6):1098-1114.e16. PubMed ID: 32169218
[TBL] [Abstract][Full Text] [Related]
16. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
Datta M; Coussens LM; Nishikawa H; Hodi FS; Jain RK
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():165-174. PubMed ID: 31099649
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus immune evasion of myeloid lineage cells.
Brinkmann MM; Dağ F; Hengel H; Messerle M; Kalinke U; Čičin-Šain L
Med Microbiol Immunol; 2015 Jun; 204(3):367-82. PubMed ID: 25776081
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment.
Kumar V; Gabrilovich DI
Immunology; 2014 Dec; 143(4):512-9. PubMed ID: 25196648
[TBL] [Abstract][Full Text] [Related]
19. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment.
Lam KC; Araya RE; Huang A; Chen Q; Di Modica M; Rodrigues RR; Lopès A; Johnson SB; Schwarz B; Bohrnsen E; Cogdill AP; Bosio CM; Wargo JA; Lee MP; Goldszmid RS
Cell; 2021 Oct; 184(21):5338-5356.e21. PubMed ID: 34624222
[TBL] [Abstract][Full Text] [Related]
20. Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies.
Ngiow SF; Young A
Front Immunol; 2020; 11():1633. PubMed ID: 32849557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
